Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on EBS shares. Cowen cut their target price on shares of Emergent BioSolutions from $40.00 to $30.00 in a research note on Friday, April 29th. Cowen cut their target price on shares of Emergent BioSolutions from $40.00 to $30.00 in a research note on Friday, April 29th. Cantor Fitzgerald cut shares of Emergent BioSolutions from an "overweight" rating to a "neutral" rating in a research note on Friday, April 29th. StockNews.com cut shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Saturday, May 7th. Finally, Chardan Capital dropped their price objective on shares of Emergent BioSolutions from $75.00 to $65.00 in a research note on Friday, April 29th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $49.17.
Emergent BioSolutions Price Performance
Shares of NYSE:EBS traded down $0.83 on Tuesday, reaching $29.72. The company's stock had a trading volume of 721,553 shares, compared to its average volume of 666,974. The company has a 50-day simple moving average of $31.48 and a 200 day simple moving average of $36.83. The company has a market cap of $1.48 billion, a P/E ratio of 17.59 and a beta of 0.98. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.38 and a current ratio of 3.92. Emergent BioSolutions has a 52-week low of $26.85 and a 52-week high of $65.09.
Emergent BioSolutions (NYSE:EBS - Get Rating) last released its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($1.24). The firm had revenue of $242.70 million during the quarter, compared to the consensus estimate of $268.77 million. Emergent BioSolutions had a return on equity of 12.22% and a net margin of 6.02%. Emergent BioSolutions's revenue was down 38.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.33 EPS. As a group, equities research analysts anticipate that Emergent BioSolutions will post -0.7 EPS for the current fiscal year.
Insider Transactions at Emergent BioSolutions
In other news, Director Kathryn C. Zoon sold 1,173 shares of the firm's stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $31.52, for a total value of $36,972.96. Following the completion of the sale, the director now owns 19,654 shares in the company, valued at approximately $619,494.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Kathryn C. Zoon sold 1,173 shares of Emergent BioSolutions stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $31.52, for a total transaction of $36,972.96. Following the completion of the sale, the director now owns 19,654 shares in the company, valued at approximately $619,494.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kathryn C. Zoon sold 1,996 shares of Emergent BioSolutions stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $35.53, for a total transaction of $70,917.88. Following the sale, the director now owns 12,381 shares of the company's stock, valued at approximately $439,896.93. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.
